Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

CompletedOBSERVATIONAL
Enrollment

81

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Colon Cancer Liver Metastasis
Interventions
DRUG

Icosapent Ethyl Oral Capsule

Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.

OTHER

Placebo

Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).

Trial Locations (2)

Unknown

St James's University Hospital, Leeds

University of Liverpool, Liverpool

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Massachusetts General Hospital

OTHER

collaborator

Massachusetts Institute of Technology

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

University of Bradford

OTHER

lead

University of Leeds

OTHER

NCT04682665 - Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases | Biotech Hunter | Biotech Hunter